serine/threonine Kinase 33 Proteine (STK33)

Human serine/threonine Kinase 33 (STK33) Interaktionspartner

1. Dysregulated HIF1alpha (zeige HIF1A Proteine)/STK33 signaling promotes pancreatic ductal adenocarcinoma (PDAC) growth and progression, this suggests that STK33 is a candidate therapeutic target to improve PDAC treatment.

2. STK33 is a potential oncogene (zeige RAB1A Proteine) and plays an important role in tumorigenesis of HSCC via regulation of numerous genes.

3. STK33 plays an essential role in hepatocellular proliferation and liver tumorigenesis. STK33 may bind directly to c-Myc (zeige MYC Proteine) and increase its transcriptional activity.

4. Results show that STK33 is a potential oncogene (zeige RAB1A Proteine) and a promising diagnostic marker for hypopharyngeal squamous cell carcinoma (HSCC). STK33 may promote tumorigenesis and progression of HSCC, and serve as a valuable molecular target for treatment of HSCC.

5. STK33 can promote cell migration and invasion and suppress p53 (zeige TP53 Proteine) gene expression in the NL9980 and L9981 large cell lung cancer cell lines. In addition, this protein also promotes epithelial-mesenchymal transition.

6. The STK33-linked SNP rs4929949 is associated with obesity and BMI in two independent cohorts of Swedish and Greek children.

7. STK33 downregulation or dominant mutant overexpression had no effect on KRAS signaling or survival of cancer cells.

8. STK33/Stk33 expression pattern resembles those of some related members of the calcium/calmodulin dependent kinase group

Mouse (Murine) serine/threonine Kinase 33 (STK33) Interaktionspartner

1. Stk33 protein resides in the cytoplasm and partially co-localizes with the caudal end of the manchette, a transient structure that guides tail elongation, in elongating spermatids, and loss of Stk33 leads to the appearance of a tight, straight and elongated manchette.

2. STK33 plays an essential role in hepatocellular proliferation and liver tumorigenesis. STK33 may bind directly to c-Myc (zeige MYC Proteine) and increase its transcriptional activity.

3. Double-immunostaining experiments with antibodies against Stk33 and vimentin (zeige VIM Proteine) showed a striking colocalization of Stk33 and vimentin (zeige VIM Proteine) in the hypothalamus.

4. STK33/Stk33 expression pattern resembles those of some related members of the calcium/calmodulin dependent kinase group

5. STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells.